Pharmaceutical

Gilead Sciences reports net income rise in Q2 2024

Gilead Sciences has reported net income attributable to the company at $1.61bn, up from $1.04bn in the corresponding quarter of 2023.

Aug 11, 2024 - 04:00
Gilead Sciences reports net income rise in Q2 2024
Gilead Sciences has reported net income attributable to the company at $1.61bn, up from $1.04bn in the corresponding quarter of 2023.
Read the original article

Tags:

Previous Article

Adaptimmune leads in soft tissue sarcoma therapy with first TCR approval

Next Article

WuXi Biologics and Medigene link on T cell engagers for cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

NYBC rolls out $50m fund to advance blood and cellular therapy innovations

NYBC rolls out $50m fund to advance blood and cellular ...

May 12, 2023

South Korea seeks to accelerate drug reimbursement administration process

South Korea seeks to accelerate drug reimbursement admi...

Jun 22, 2024

STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowledges Merck, Pfizer broke off partnerships over buzzy science

STAT+: Dewpoint Therapeutics cuts 15% of staff, acknowl...

Jan 16, 2024